A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. | Retrospective cohort study of trifluridine tipiracil TAS-102 plus bevacizumab versus trifluridine tipiracil monotherapy for metastatic colorectal cancer